Another vaccine company Rongsheng Bio sprints for the market. Is the post -epidemic era vaccine?

In recent years, affected by the repeated epidemic, the vaccine has become a familiar topic in most people's lives. Vaccine giants such as Kangshino and Koxing have also attracted everyone's attention, but it is also affected by this. Other vaccine companies are also affected. It has also begun to embark on the road of capitalization. Especially recently, a vaccine company has begun to sprint for listing. Many people have become a good business in the post -epidemic era?

1. There is another vaccine company sprinting for listing

According to the "Science and Technology Board Daily" report, Shanghai Rongsheng Biopharmaceutical Co., Ltd. (hereinafter referred to as Rongsheng Bio) IPO application was accepted by the Shanghai Stock Exchange. The company plans to raise funds of 1.25 billion yuan for vaccine research and development and industrialization projects.

According to the prospectus, the business of Rongsheng Bio is mainly vaccine and in vitro diagnosis. In recent years, vaccines are the main. In 2021, more than 82%of Rongsheng Bio's main business revenue contributed by vaccine products.

The aforementioned vaccine also refers to the hydrating vaccine (December-12 years). This is also the only vaccine product that has been approved for listing and sold. According to the prospectus, the vaccine was approved for listing in October 2016. Because of "not adding human hemoglobin and gelatin, the adverse reaction rate was low after vaccination, and the product market recognition gradually increased."

According to the Huaxia Times, public information shows that Rongsheng Bio is a modern biomedical company focusing on the R & D, production and sales of vaccines and in vitro diagnostic reagents. Established in 1988, the company was founded by the main business diagnostic reagent business at the beginning of its establishment. It is one of the earliest companies in China that are engaged in internal diagnostic reagents. The main products are used for diagnosis of infectious diseases, with enzymes and biochemical reagents. In 2002, Rongsheng Bio began to carry out the research and development of vaccines.

In terms of performance, Rongsheng Bio just turned his losses in 2021. From 2019 to 2021, the operating income achieved operating income of 124 million yuan, 168 million yuan, and 262 million yuan, respectively, and the non-net profit of the same period was -2532.78, -3500.75 and 17.774 million yuan, respectively.

In 2014, the familiar new crown vaccine giant Zhi Fei Biological has signed the "Equity Transfer Framework Agreement" with Zhu Shaorong, a actual controller of Rongsheng, to acquire 85%equity of Rongsheng Bio's business and assets related to vaccine products, and thus will Rong Rong The peculiarborn vaccine and influenza vaccine were developed in the bag. However, by January 2016, the chickenpox vaccine developed by Rongsheng Bio has not obtained the production number approval and GMP certificate, so the "Equity Transfer Framework Agreement" was terminated. Shortly after the agreement was terminated, in October 2016, the first vaccine product of the Vaccium of Rongsheng Bio was approved to be listed.

In addition to chickenpox vaccines, Rongsheng Bio-research projects also include frozen-dried people with rabies vaccine (Vero cells), frozen dried people with rabies vaccine (ductive cells), chickenpox-shingles vaccine, tetravalent influenza virus cracks Vaccine (MDCK cells) and 16 -valent pneumococcal polysaccharide binding vaccine.

Second, the post -epidemic era vaccine is a good business?

Seeing the listing of Rongsheng Bio sprinting, the greatest feeling is that the epidemic really brought a huge development opportunity to the entire biopharmaceutical industry, especially the vaccine industry, which has been continuously improved by everyone's health awareness. At present, companies like Rongsheng Bio are sprinting on the market. What should we think of this? What should I think of the future of Rongsheng creatures?

First of all, the vaccine and in vitro detection market do have strong market advantages. For the current Chinese market, with the development of the market in the post -epidemic era, more and more users have begun to recognize the value of the vaccine. In addition to the country's mandatory vaccine, the trend of users' own choice of vaccination has begun to rise, the vaccine The space for market development has begun to increase.

According to data from the China Business Information Network, in recent years, the size of the Chinese vaccine market has increased from 25.3 billion yuan in 2017 to 64 billion yuan in 2020, and the average annual growth rate of compound annual growth in 2016-2020 was 36.26%. The scale of China's vaccine market is expected to reach 89.3 billion yuan (excluding new crown pneumonia vaccines) in 2022.

At the same time, the in vitro detection market is also developing rapidly. The so -called in vitro testing is the most familiar with the new crown's antigen detection and the early pregnancy test that everyone is familiar with. The creature itself relies on in vitro testing, and has established two major product lines of immune diagnostic reagents and biochemical diagnostic reagents, creating a number of products such as enzyme -linked immune method, condensation reaction method, colloidal gold method, dry fluorescent lighting method, biochemical diagnostic reagents and other products Pipeline.

Therefore, in the context of the current market development, Rongsheng Bio has achieved a good market development prospect. It is worth looking forward to. Rongsheng Bio itself is worth looking forward to.

Secondly, the advantages of Rongsheng creatures are relatively obvious. As a vaccine listed company, the main market advantages of Rongsheng Bio are concentrated on the two tracks of the vaccine and in vitro detection. By careful analysis of the prospectus of Rongsheng Bio, we can see that the company's own advantages are relatively comparison obviously:

The first is that the main vaccine has two prosperous production and sales, and the data is quite good. The poisoning vaccine that was once seen by the giant Zhifei Biological was indeed the core advantage of the Rongsheng creature. From 2019 to 2021, the vaccine has two prosperous production and sales and the volume and price rise. During this period, the vaccine sales volume was 397,300, 899,400, and 1.565 million, priced at 131.55 yuan/branch, 133.48 yuan/branch, 137.36 yuan/branch, and the overall gross profit level reached more than 80 %, so as In one fell swoop, Rongsheng Bio achieved a profit. Second, the advantages of in vitro testing business are relatively obvious. The syphilitic tetine -pyromine redness developed by Rongsheng Bio has not increased heated serum test diagnostic reagents, and has maintained the first place in China for many years. When Rongsheng Bio was established in 1988, it has been in the in vitro test market. The advantages of this market have always been very significant.

Third, Rongsheng Bio is a weak marketing company. For most biopharmaceutical companies, marketing is the most critical link in the market, but Rongsheng Bio is a very well -known weak marketing company. The prospectus shows that there are only 45 salespersons in Rongsheng Bio. In the case of few sales staff, they have a good performance in the first two businesses, at least proved that the company's products are relatively strong.

Third, the disadvantages of Rongsheng Biological are also prominent. If the advantages of Rongsheng creatures are obvious, the disadvantages of Rongsheng creatures are also very prominent. This is a company with very obvious advantages and disadvantages. The disadvantage is mainly concentrated:

The first is that there are too few main vaccine products, and the products in research and layout also lack differentiated advantages. We will see through the previous article that the core market advantages of Rongsheng Bio are vaccine products, but its real vaccine is only a chickenpox vaccine. Although its technical advantages are still obvious, the vaccine companies eat a little trick to eat all the tricks throughout the way The market gameplay is becoming increasingly difficult in the current market environment, and although other research products are also popular vaccines, almost every product has a lot of competitors. If the absolute advantages of chickenpox vaccine will be in the problem of competition in the Red Sea.

Second, in vitro testing products are difficult to take into account, and market space is compressed. Although in vitro testing products is an advantageous product of Rongsheng Bio, the entire market's atrophy is more obvious, and there are few companies that can be compatible with two tracks on the market. Faced with the reality of increasingly ribbon in vitro detection products, Rong Rong, Rong Rong, Rong. The pressure of Sheng creatures is actually increasing.

Third, the long -term disadvantages of the macro environment have begun to stand up. In recent years, the number of newborns has begun to decline, and the overall trend has begun to form. For companies such as the vaccine market, especially Rongsheng Bio, which is at its core, it will be a big impact. The diversified products are either tolerate the pressure of the possible decline in demand.

Therefore, for Rongsheng Bio, companies with such obvious advantages and disadvantages can sprint listings really effective? We might as well look forward to it and see what the final result is?

- END -